睿知中国医院研究地图
候选清单

正在招募胰腺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 8 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 79 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed pancreatic ductal adenocarcinoma;

    入选标准第 3 条

    Postoperative pathological stage (pTNM): T1-3, N0-2, M0;

    入选标准第 5 条

  3. ECOG performance status score 0-1;

    入选标准第 10 条

  4. Positive serology for HIV, Treponema pallidum or HCV;

    排除标准第 8 条

    Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;

    排除标准第 22 条

  5. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;

    入选标准第 12 条

    Pregnant or lactating women;

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05911217,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation in the clinical trial; fully understand, be informed about this study and have signed the ICF; willing to follow and able to complete all study procedures;
  2. Aged 18 to 79 years;
  3. Histologically confirmed pancreatic ductal adenocarcinoma;
  4. Macroscopic complete tumor removal ;
  5. Postoperative pathological stage (pTNM): T1-3, N0-2, M0;
  6. Immunohistochemistry (IHC) staining of subject's tumor tissue sample is CLDN18.2-positive;
  7. Subjects had recovered from surgery and had received months of standard adjuvant therapy;
  8. Abnormal of Specific tumor marker level;
  9. With sufficient venous access for leukapheresis collection;
  10. ECOG performance status score 0-1;
  11. Adequate organ function;
  12. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy;

排除标准:Exclusion Criteria:

  1. Prior neoadjuvant therapy for pancreatic cancer;
  2. Subjects with borderline resectable pancreatic cancer;
  3. Present or past history of metastatic or locally recurrent pancreatic cancer;
  4. Evidence of malignant ascites;
  5. Subjects had diseases that may interfere with CA19-9 level.
  6. Toxicities caused by previous treatment have not recovered to CTCAE ≤ grade 2, except alopecia and other tolerable events as judged by the investigator or laboratory abnormalities allowed in this study;
  7. Pregnant or lactating women;
  8. Positive serology for HIV, Treponema pallidum or HCV;
  9. Any active infections;
  10. Clinically significant thyroid dysfunction;
  11. Previous allergy to immunotherapy and related drugs, allergy to CT041 ingredients and other serious allergic history;
  12. Subjects who may be at high risk for potential digestive tract bleeding or perforation;
  13. Known active autoimmune disease, including but not limited to, psoriasis or rheumatoid arthritis, or other conditions requiring long-term immunosuppressive therapy;
  14. Subjects who have a history of organ transplantation or are awaiting organ transplantation;
  15. Subjects who require anticoagulant therapy;
  16. Subjects who are receiving or are expected to require long-term antiplatelet therapy during the study;
  17. Subjects who have experienced major surgery or have significant trauma within 4 weeks before apheresis, or who are expected to undergo major surgery during the study period;
  18. Previously received any gene-modified cell therapies (including CAR T, TCR T);
  19. Subjects who have other serious diseases that may restrict them from participating in the study assessed by investigators;
  20. Subjects with oxygen saturation ≤ 95%;
  21. Subjects who have signs of central nervous system diseases or clinically significant neurological examination abnormalities;
  22. Subjects who have other uncured malignant tumors in the past 3 years or at the same time, except those with very low degree of malignancy such as cervical cancer in situ and basal cell carcinoma of skin;
  23. Vaccination with live attenuated vaccines within 4 weeks prior to apheresis or planned during the study;
  24. Subjects who are unable to or unwilling to comply with the requirements of the study protocol as assessed by investigators.

引自 ClinicalTrials.gov, NCT05911217, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05911217,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05911217